PortalPublikationenComparative Efficacy of Talquetamab vs. Current Treatments i...

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Standard

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. / Einsele, Hermann; Moreau, Philippe; Bahlis, Nizar; Bhutani, Manisha; Vincent, Laure; Karlin, Lionel; Perrot, Aurore; Goldschmidt, Hartmut; van de Donk, Niels W C J; Ocio, Enrique M; Martinez-Lopez, Joaquin; Rodríguez-Otero, Paula; Dytfeld, Dominik; Diels, Joris; Strulev, Vadim; Haddad, Imene; Renaud, Thomas; Ammann, Eric; Cabrieto, Jedelyn; Perualila, Nolen; Gan, Ryan; Zhang, Youyi; Parekh, Trilok; Albrecht, Claire; Weisel, Katja; Mateos, Maria-Victoria.

in: ADV THER, Jahrgang 41, Nr. 4, 04.2024, S. 1576-1593.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Einsele, H, Moreau, P, Bahlis, N, Bhutani, M, Vincent, L, Karlin, L, Perrot, A, Goldschmidt, H, van de Donk, NWCJ, Ocio, EM, Martinez-Lopez, J, Rodríguez-Otero, P, Dytfeld, D, Diels, J, Strulev, V, Haddad, I, Renaud, T, Ammann, E, Cabrieto, J, Perualila, N, Gan, R, Zhang, Y, Parekh, T, Albrecht, C, Weisel, K & Mateos, M-V 2024, 'Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma', ADV THER, Jg. 41, Nr. 4, S. 1576-1593. https://doi.org/10.1007/s12325-024-02797-x

APA

Einsele, H., Moreau, P., Bahlis, N., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., Martinez-Lopez, J., Rodríguez-Otero, P., Dytfeld, D., Diels, J., Strulev, V., Haddad, I., Renaud, T., Ammann, E., Cabrieto, J., ... Mateos, M-V. (2024). Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. ADV THER, 41(4), 1576-1593. https://doi.org/10.1007/s12325-024-02797-x

Vancouver

Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L et al. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. ADV THER. 2024 Apr;41(4):1576-1593. https://doi.org/10.1007/s12325-024-02797-x

Bibtex

@article{a6265cf5cc534bedb9f07ff6f834b8b5,
title = "Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma",
abstract = "INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons.METHODS: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model.RESULTS: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001.CONCLUSION: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM.TRIAL REGISTRATION: MonumenTAL-1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584.",
keywords = "Humans, Multiple Myeloma/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use",
author = "Hermann Einsele and Philippe Moreau and Nizar Bahlis and Manisha Bhutani and Laure Vincent and Lionel Karlin and Aurore Perrot and Hartmut Goldschmidt and {van de Donk}, {Niels W C J} and Ocio, {Enrique M} and Joaquin Martinez-Lopez and Paula Rodr{\'i}guez-Otero and Dominik Dytfeld and Joris Diels and Vadim Strulev and Imene Haddad and Thomas Renaud and Eric Ammann and Jedelyn Cabrieto and Nolen Perualila and Ryan Gan and Youyi Zhang and Trilok Parekh and Claire Albrecht and Katja Weisel and Maria-Victoria Mateos",
note = "{\textcopyright} 2024. The Author(s).",
year = "2024",
month = apr,
doi = "10.1007/s12325-024-02797-x",
language = "English",
volume = "41",
pages = "1576--1593",
journal = "ADV THER",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

AU - Einsele, Hermann

AU - Moreau, Philippe

AU - Bahlis, Nizar

AU - Bhutani, Manisha

AU - Vincent, Laure

AU - Karlin, Lionel

AU - Perrot, Aurore

AU - Goldschmidt, Hartmut

AU - van de Donk, Niels W C J

AU - Ocio, Enrique M

AU - Martinez-Lopez, Joaquin

AU - Rodríguez-Otero, Paula

AU - Dytfeld, Dominik

AU - Diels, Joris

AU - Strulev, Vadim

AU - Haddad, Imene

AU - Renaud, Thomas

AU - Ammann, Eric

AU - Cabrieto, Jedelyn

AU - Perualila, Nolen

AU - Gan, Ryan

AU - Zhang, Youyi

AU - Parekh, Trilok

AU - Albrecht, Claire

AU - Weisel, Katja

AU - Mateos, Maria-Victoria

N1 - © 2024. The Author(s).

PY - 2024/4

Y1 - 2024/4

N2 - INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons.METHODS: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model.RESULTS: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001.CONCLUSION: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM.TRIAL REGISTRATION: MonumenTAL-1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584.

AB - INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons.METHODS: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model.RESULTS: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001.CONCLUSION: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM.TRIAL REGISTRATION: MonumenTAL-1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584.

KW - Humans

KW - Multiple Myeloma/drug therapy

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

U2 - 10.1007/s12325-024-02797-x

DO - 10.1007/s12325-024-02797-x

M3 - SCORING: Journal article

C2 - 38402374

VL - 41

SP - 1576

EP - 1593

JO - ADV THER

JF - ADV THER

SN - 0741-238X

IS - 4

ER -